Liu Jun, Ostrowski Mario
Clinical Sciences Division, University of Toronto, Room 6352, Medical Sciences Building, 1 King's College Circle, Toronto, ON, M5S1A8, Canada.
Department of Immunology, University of Toronto, Toronto, ON, Canada.
AIDS Res Ther. 2017 Sep 12;14(1):43. doi: 10.1186/s12981-017-0165-8.
Finding new adjuvants is an integrated component of the efforts in developing an effective HIV-1 vaccine. Compared with traditional adjuvants, a modern adjuvant in the context of HIV-1 prevention would elicit a durable and potent memory response from B cells, CD8 T cells, and NK cells but avoid overstimulation of HIV-1 susceptible CD4 T cells, especially at genital and rectal mucosa, the main portals for HIV-1 transmission. We briefly review recent advances in the studies of such potential targeted adjuvants, focusing on three classes of molecules that we study: TNFSF molecules, TLRs agonists, and NODs agonists.
寻找新型佐剂是开发有效HIV-1疫苗工作的一个重要组成部分。与传统佐剂相比，在HIV-1预防背景下的现代佐剂能够引发B细胞、CD8 T细胞和NK细胞产生持久且强效的记忆反应，但能避免过度刺激HIV-1易感的CD4 T细胞，尤其是在HIV-1传播的主要途径——生殖器和直肠黏膜处。我们简要回顾了此类潜在靶向佐剂研究的最新进展，重点关注我们所研究的三类分子：肿瘤坏死因子超家族（TNFSF）分子、Toll样受体（TLRs）激动剂和核苷酸结合寡聚化结构域（NODs）激动剂。
